Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co‐administered enteric‐coated mycophenolate sodium
Authors:
- 5 July 2005
- journal article
- clinical trial
- Published by Wiley in Clinical Transplantation
- Vol. 19 (4) , 551-558
Abstract
Abstract: Enteric‐coated mycophenolate sodium (EC‐MPS) (myfortic®) is an advanced formulation delivering mycophenolic acid (MPA), designed to improve MPA‐related upper gastrointestinal adverse events by delaying the release of MPA until the small intestine. A randomized, calcineurin inhibitor crossover, steady‐state pharmacokinetic study in stable renal transplant patients receiving EC‐MPS demonstrated increased MPA exposure of 19% higher, MPA Cmax,ss 19% lower and MPA Cmin,ss approximately twofold higher with tacrolimus, than cyclosporine microemulsion. No study drug‐related adverse events were recorded, but mean blood glucose concentration was higher in patients receiving tacrolimus (p = 0.031). The dose changes in relation to MPA exposure in patients is dependent on the clinical situation and may not always be warranted. These observations should be taken into consideration when switching from one calcineurin inhibitor to another, but the final dosage should be based on both this pharmacokinetic data and the clinical situation.Keywords
This publication has 14 references indexed in Scilit:
- Enteric Coated Mycophenolate Sodium is Therapeutically Equivalent to Mycophenolate Mofetil in de novoRenal Transplant PatientsAmerican Journal of Transplantation, 2004
- Enteric-Coated Mycophenolate Sodium can be Safely Administered in Maintenance Renal Transplant Patients: Results of a 1-Year StudyAmerican Journal of Transplantation, 2004
- Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolateTransplantation Proceedings, 2001
- Effect of Cyclosporine on Mycophenolic Acid Area Under the Concentration–Time Curve in Pediatric Kidney Transplant RecipientsTherapeutic Drug Monitoring, 2001
- Tacrolimus/mycophenolate mofetil vs cyclosporine/mycophenolate mofetil: comparison of mycophenolate acid trough levels and coronary vasomotor functionThe Journal of Heart and Lung Transplantation, 2001
- Mycophenolate mofetil is superior in combination with tacrolimus compared to cyclosporine for immunosuppressive therapy after liver transplantationTransplantation Proceedings, 2001
- Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppressionPediatric Nephrology, 2000
- Drug Interaction Between Mycophenolate Mofetil and Tacrolimus Detectable Within Therapeutic Mycophenolic Acid Monitoring in Renal Transplant PatientsTherapeutic Drug Monitoring, 1999
- The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation*Clinical Pharmacology & Therapeutics, 1998
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998